ClinicalTrials.gg
CompletedNCT07232732Updated Nov 9, 2026

A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity

A Phase 1 interventional study of LY3549492 in Healthy, Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Updated Nov 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 118 studies in Obesity by Eli Lilly and Company — 31 open to participants now, 55 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.

Enrollment
87th of 117
120 · median 267
Started
2025
with 27 others
Phase 1
40 of 118
9 open now
Registered
89th of 118
by date

Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 87th largest by enrollment of the 117 interventional ones that give a count, is one of 28 that started in 2025, is one of 40 in phase 1, and was the 89th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

31 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Obesity by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks.

03

Conditions studied

  • Healthy
  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a level of less than 6.5 percent (%) at screening.
  • Have a (BMI) of 25.0 to 45.0 kilogram per square meter (kg/m²), inclusive, at screening
  • Participants assigned male at birth (AMAB) or participants assigned female at birth (AFAB) who are individual of (INOCBP) use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Have obesity induced by endocrine disorders such as Cushing's syndrome or Prader Willi syndrome.
  • Have any of the following conditions at screening,

    • supine systolic blood pressure of 160 millimeter of mercury (mmHg) or greater
    • supine diastolic blood pressure of 100 mmHg or greater, or
    • resting pulse rate of greater than 95 beats per minute (bpm) or less than 45 bpm. (Note: white-coat hypertension is excluded; therefore, if a repeated measurement of blood pressure after at least 5 minutes shows values within the range, the participant can be included).
  • Have had any of the following within 6-months prior to screening

    • myocardial infarction
    • unstable angina
    • coronary artery bypass graft
    • percutaneous coronary intervention. (Note: diagnostic angiograms are permitted)
    • cerebrovascular accident or decompensated congestive heart failure, or
    • New York Health Association Class III or IV heart failure.
  • Have serum triglyceride of 5 millimoles per liter (mmol/L) or greater (442 milligrams per deciliter [mg/dL]) at screening
  • Have had any exposure to glucagon-like peptide-1 (GLP-1) analogs or other related compounds within the 3 months prior to screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    LY3549492 (Treatment Group 1)

    LY3549492 administered orally.

    Drug: LY3549492

  • Experimental
    LY3549492 (Treatment Group 2)

    LY3549492 administered orally.

    Drug: LY3549492

  • Experimental
    LY3549492 (Treatment Group 3)

    LY3549492 administered orally.

    Drug: LY3549492

  • Experimental
    LY3549492 (Treatment Group 4)

    LY3549492 administered orally.

    Drug: LY3549492

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline through end of the Follow-up Period (Week 10)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3549492

    PK: Cmax of LY3549492

    Time frame: Predose on Day 1 through end of the Follow-up Period (Week 10)

  2. PK: Observed Drug Trough Concentration (Ctrough) of LY3549492

    PK: Ctrough of LY3549492

    Time frame: Predose on Day 1 through end of the Follow-up Period (Week 10)

  3. PK: Area Under the Concentration Versus Time Curve (AUC) of LY3549492

    PK: AUC of LY3549492

    Time frame: Predose on Day 1 through end of the Follow-up Period (Week 10)

07

Study locations

3 sites
  • Fortrea Clinical Research Unit
    Daytona Beach, Florida 32117, United States
  • Fortrea Clinical Research Unit
    Dallas, Texas 75247, United States
  • Fortrea Clinical Research Unit
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Jul 2026, 8 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 8 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 18, 2025
StartActual
Oct 27, 2025
Primary completionActual
Jul 17, 2026
CompletionActual
Jul 17, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 16, 2026→Jul 17, 2026
Nov 9, 2026
Study completion
Jul 16, 2026→Jul 17, 2026
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Jul 16, 2026→Jul 17, 2026
    Study completion Jul 16, 2026→Jul 17, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07232732
Responsible party
Sponsor
First posted
Nov 18, 2025
Start date
Oct 27, 2025
Primary completion
Jul 17, 2026
Completion
Jul 17, 2026
Last update
Nov 9, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naperiglipron

Start the discussion